Role of Endoplasmic Reticulum Stress and c-Jun NH2-Terminal Kinase Pathways in Inflammation and Origin of Obesity and Diabetes
- From the Departments of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts
- Address correspondence and reprint requests to Gökhan S. Hotamisligil, MD, PhD, 665 Huntington Ave., Bldg. I, Rm. 205, Boston, MA 02115. E-mail: ghotamis{at}hsph.harvard.edu
Abstract
Metabolic and immune systems are the most fundamental requirements for survival, and many metabolic and immune response pathways or nutrient- and pathogen-sensing systems have been evolutionarily highly conserved. Consequently, metabolic and immune pathways are also highly integrated and interdependent. In the past decade, it became apparent that this interface plays a critical role in the pathogenesis of chronic metabolic diseases, particularly obesity and type 2 diabetes. Importantly, the inflammatory component in obesity and diabetes is now firmly established with the discovery of causal links between inflammatory mediators, such as tumor necrosis factor (TNF)-α and insulin receptor signaling and the elucidation of the underlying molecular mechanisms, such as c-Jun NH2-terminal kinase (JNK)- and inhibitor of nuclear factor-κB kinase–mediated transcriptional and posttranslational modifications that inhibit insulin action. More recently, obesity-induced endoplasmic reticulum stress has been demonstrated to underlie the initiation of obesity-induced JNK activation, inflammatory responses, and generation of peripheral insulin resistance. This article will review the link between stress, inflammation, and metabolic disease, particularly type 2 diabetes, and discuss the mechanistic and therapeutic opportunities that emerge from this platform by focusing on JNK and endoplasmic reticulum stress responses.
- ER, endoplasmic reticulum
- IKK, inhibitor of nuclear factor-κB kinase
- IRS, insulin receptor substrate
- JIP, JNK-interacting protein
- JNK, c-Jun NH2 terminal kinase
- TNF, tumor necrosis factor
Footnotes
-
G.S.H. has received honoraria from Merck, Lilly, and Taisho Pharm for speaking engagements and has received research funding from Eli Lilly.
This article is based on a presentation at a symposium. The symposium and the publication of this article were made possible by an unrestricted educational grant from Servier.
-
- Accepted June 6, 2005.
- Received April 14, 2005.
- DIABETES














